drugset / Trial / NCT03279861
Sacubitril-valsartan Versus Usual Anti-hypertensives in LVAD
RandomizedCrossoverOpen-labelTreatment
Summary
This pilot, feasibility study evaluates the efficacy of sacubitril-valsartan (Entresto) versus usual anti-hypertensive medications in patients with left ventricular assist devices (LVAD). It also measures diurnal blood pressure variations in the context of continuous flow physiology.
Timeline
- Start
- 2017-11
- Primary completion
- 2018-11
- Completion
- 2019-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Sacubitril-Valsartan | Unknown | 97 mg | — |
| Comparator | Sacubitril-Valsartan | Unknown | 103 mg | — |
| Comparator | Valsartan | Small molecule | 160 mg | — |